Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Endpoint-Blind, Parallel Group Study to Demonstrate the Non-Inferiority of the Subunit Influenza Vaccine Influvac® to the Subunit Influenza Vaccine Agrippal® in Healthy Children, Adults and Elderly in China.

NCT00325260 is registered in ClinicalTrials.gov with Solvay Pharmaceuticals as lead sponsor.

NCT NCT00325260
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00325260 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Endpoint-Blind, Parallel Group Study to Demonstrate the Non-Inferiority of the Subunit Influenza Vaccine Influvac® to the Subunit Influenza Vaccine Agrippal® in Healthy Children, Adults and Elderly in China.
Lead sponsor
Solvay Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2006
Completion date
Not reported
Enrollment
900
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy